Gene panel testing detects important genetic alterations in ulcerative colitis-associated colorectal neoplasia

Ulcerative colitis-associated neoplasia (UCAN) harbors unique genetic alterations and mutational tendencies. The clinical application of gene panel testing enables precision medicine by tailoring treatment to individual gene alterations. We hypothesized that gene panel testing may detect clinically important genetic alterations in UCAN, with potential usefulness for the diagnosis and treatment of UCAN. In the present study, gene panel testing was used to identify genetic alterations in UCAN, and the possibility of clinical utility of gene panel testing in UCAN was investigated. The present study included 15 patients with UCAN, and gene panel testing was performed to identify genetic alterations associated with diagnosis and treatment. Genetic alterations of UCAN were compared with those of 203 patients with sporadic colorectal cancer (CRC). APC and PTEN mutations were less frequent, while RNF43 frameshift or nonsense mutations were more frequent in UCAN compared with sporadic CRC. TP53 mutations were identified in 13/15 patients (87%) with UCAN. Notably, 4/15 patients (27%) with UCAN had no genetic alterations other than TP53 mutation, while this occurred in 1/203 patients (0.5%) with sporadic CRC (P<0.001). Microsatellite instability-high was identified in 2/15 patients (13%) with UCAN. Mutational signature 3, which is associated with homologous recombination deficiency, was detected in 14/15 patients (93%) with UCAN, and enriched in UCAN compared with sporadic CRC (P=0.030). In conclusion, gene panel testing can detect important genetic alterations that can be useful for diagnosis and treatment in UCAN, and may provide clinicians with important information for tailored treatment strategies.

[1]  M. Oberley,et al.  Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. , 2021, Journal of the National Cancer Institute.

[2]  Shujiro Okuda,et al.  Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer , 2021, Journal of Gastroenterology.

[3]  M. Nykter,et al.  Genetic and epigenetic characteristics of inflammatory bowel disease associated colorectal cancer. , 2021, Gastroenterology.

[4]  A. Ristimäki,et al.  Somatic mutation profiles as molecular classifiers of ulcerative colitis‐associated colorectal cancer , 2021, International journal of cancer.

[5]  T. Ried,et al.  Molecular characterization of ulcerative colitis-associated colorectal carcinomas , 2020, Modern Pathology.

[6]  K. Chayama,et al.  Genomic Landscape of Early-stage Colorectal Neoplasia Developing From the Ulcerative Colitis Mucosa in the Japanese Population. , 2020, Inflammatory bowel diseases.

[7]  Shujiro Okuda,et al.  RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer , 2020, Oncology reports.

[8]  AJCC Cancer Staging Manual 8th Edition , 2020, Definitions.

[9]  B. Ylstra,et al.  IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. , 2020, Inflammatory bowel diseases.

[10]  A. Bardelli,et al.  A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin , 2019, Clinical Cancer Research.

[11]  Jingnan Li,et al.  Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients. , 2019, Inflammatory bowel diseases.

[12]  Michelle N Wurst,et al.  Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. , 2019, Human pathology.

[13]  Ashwin N. Ananthakrishnan,et al.  ACG Clinical Guideline: Ulcerative Colitis in Adults , 2019, The American journal of gastroenterology.

[14]  Shujiro Okuda,et al.  BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer , 2019, Scientific Reports.

[15]  Shujiro Okuda,et al.  Next generation sequencing‐based gene panel tests for the management of solid tumors , 2018, Cancer science.

[16]  Marc J. Williams,et al.  Evolutionary history of human colitis-associated colorectal cancer , 2018, Gut.

[17]  T. Wakai,et al.  Genomic characterization of colitis-associated colorectal cancer , 2018, World Journal of Surgical Oncology.

[18]  Martin L. Miller,et al.  Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers , 2018, Clinical Cancer Research.

[19]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[20]  N. Matsubara,et al.  Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling , 2017, Oncotarget.

[21]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.

[22]  Yoko Yamamoto,et al.  Colitic Cancer Develops Through Mutational Alteration Distinct from that in Sporadic Colorectal Cancer: A Comparative Analysis of Mutational Rates at Each Step. , 2017, Cancer genomics & proteomics.

[23]  Shujiro Okuda,et al.  Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. , 2017, Human pathology.

[24]  Shujiro Okuda,et al.  Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine , 2016, Genome Medicine.

[25]  M. Pittman,et al.  Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. , 2016, Gastroenterology.

[26]  S. Grivennikov,et al.  Colitis-Associated and Sporadic Colon Cancers: Different Diseases, Different Mutations? , 2016, Gastroenterology.

[27]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Alan Barkun,et al.  SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. , 2015, Gastrointestinal endoscopy.

[29]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[30]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[31]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[32]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[33]  M. Choti,et al.  NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  Y. Ajioka,et al.  Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium , 1996, Journal of Gastroenterology.

[35]  Noam Harpaz,et al.  Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. , 2005, Gastroenterology.

[36]  H. Watanabe,et al.  Histological classification of the neoplastic changes arising in ulcerative colitis: a new proposal in Japan. , 1995, Journal of gastroenterology.

[37]  P. Rabinovitch,et al.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. , 1994, Gastroenterology.

[38]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[39]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[40]  B. Crohn,et al.  The sigmoidoscopic picture of chronic ulcerative colitis (non-specific) , 1925 .